The PCROWD Study (a Game Changer for Those With Precursor Myeloma)

May 18, 2021
05:00PM - 06:30PM EDT
Online Event
Overview

Patients with precursor myeloma conditions can now do more than "watch and wait". They can contribute to critical research. Precursor (MGUS and Smoldering) patients are often frustrated at the lack of accountability and action they are able to take regarding their disease. 

Dr. Irene Ghobrial, multiple myeloma specialist, has made it her mission to create studies and opportunities for precursor patients to empower themselves at diagnosis. 

Learn more about the PCROWD and PROMISE studies (for blood cancer patients and their families) and hear from one of the world's top experts on MGUS and smoldering multiple myeloma. Register today! 

Agenda
05:00 PM
Introductions
Audrey Burton-Bethke
Audrey welcomes everybody, shares the event agenda and introduces our featured speaker, Dr. Irene Ghobrial.
05:05 PM
Presentation
Irene Ghobrial, MD
Dr. Irene Ghobral, a top MGUS and smoldering multiple myeloma expert, shares about the PCROWD and PROMISE studies for precursor myeloma patients and their families.
06:00 PM
Q&A
Audience
Dr. Irene Ghobral answers the audience's questions about the PCROWD and PROMISE studies, MGUS and smoldering multiple myeloma, and related topics.
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey is a content writer and editor for the HealthTree Foundation.

Audrey joined the Myeloma Crowd as the Community Manager in 2020 after previously working in the nonprofit field for 4 years as a director of Fundraising and Development. She graduated from BYU with a major in Spanish and Nonprofit Management. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Irene Ghobrial, MD

Irene Ghobrial, MD

Irene Ghobrial, MD, is a Professor at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School and an associate member of the Broad Institute.

Irene Ghobrial, MD, is a Professor at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School and an associate member of the Broad Institute. She is Director of the Michele & Stephen Kirsch Laboratory and co-director of the Center for Prevention of Progression (CPOP) at DFCI. Additionally, she is the co-leader of the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of community oncology sites coordinated by DFCI. Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma and Waldenström Macroglobulinemia. She specifically focuses on the role of malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored or co-authored more than 250 publications and book chapters. She has received multiple awards including membership in the American Society of Clinical Investigation, the Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and the Mentor of the Year Award at DFCI in 2014. Dr. Ghobrial completed her hematology/oncology subspecialty training at the Mayo Clinic College of Medicine in Rochester, MN and internal medicine training at Wayne State University in Detroit, MI. She earned her medical degree from the Cairo School of Medicine in Egypt.